The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia: A study using the Hallym Smart Clinical Data Warehouse : Medicine

Journal Logo

Research Article: Observational Study

The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia

A study using the Hallym Smart Clinical Data Warehouse

Sohn, Jong-Hee MD, PhDa; Lee, Sang-Hwa MDa; Kwon, Young-Suk MDb,c; Kim, Jong-Ho MDb,c; Kim, Youngmi PhDc,∗; Lee, Jae Jun MDb,c,∗

Editor(s): Mancini., Vito

Author Information
Medicine 99(22):p e20240, May 29, 2020. | DOI: 10.1097/MD.0000000000020240
  • Open


1 Introduction

Benign prostate hyperplasia (BPH) is a common age-dependent disease affecting over half of men 65 years or older. Urology guidelines recommend alpha-blockers for the primary treatment of BPH.[1,2] Molecular studies have identified 3 α1-adrenergic receptor subtypes (α1A, α1B, and α1D).[3] Of these, α1A is the most abundant receptor subtype in the human prostate.[4,5] All α1-adrenergic receptor subtypes are also present in the brain, with different distributions and localization. In particular, α1A is more abundant in the hippocampus and hindbrain compared with α1B; therefore, there is a potential risk of adverse effects on cognitive function.[6–9]

Tamsulosin is the most widely used α1-adrenergic receptor antagonist. Unlike other α1-adrenergic receptor antagonists, tamsulosin is 10- to 38-fold more selective for α1A versus the α1B subtypes.[10] Radio-ligand assay studies have reported that tamsulosin has a binding affinity comparable to its α1A affinity for dopaminergic (D3) and serotonergic (5-HT1A) receptors.[11] Since tamsulosin has a strong affinity for all neurotransmitter receptors (α1A-adrenergic, dopaminergic, and serotonergic) that regulate and modulate important central nervous system functions, including mood, affect, attention, learning, and memory, previous investigators hypothesized that tamsulosin may increase the risk of developing dementia.[12,13]

One study reported an association between the prescription of tamsulosin and a new diagnosis of dementia, such as Alzheimer disease (AD).[13] However, data regarding the association between tamsulosin and dementia are conflicting,[14] and clinical researchers have pointed out limitations of the original study.[15,16]

The pathophysiology of AD is thought to begin many years before a diagnosis of AD dementia. There is a postulated temporal lag of at least 10 years between the deposition of Aβ and the clinical syndrome of AD dementia.[17] The associations observed in previous studies were over a median time of <5 years (19.8 vs 56.43 months), which is too short to cause dementia.[13,14] Due to inevitable limitations of clinical studies, the relationship between the use of tamsulosin and risk of dementia remains unclear.

Therefore, we investigated possible associations between the use of tamsulosin and cognitive decline in patients with AD using the Smart Clinical Data Warehouse (CDW) over a period of 10 years.

2 Patients and methods

2.1 Study population and design

We retrospectively investigated clinical data using the clinical big data analytic solution Smart CDW from Hallym University Medical Center (HUMC) from 2009 to 2019. The Smart CDW is based on the QlikView Elite Solution and is used at the 5 HUMC hospitals. It offers electronic medical record (EMR) text data analysis and integrated analysis of fixed data. Using the Smart CDW, we collected clinical data for patients with probable AD who had completed the Mini-Mental State Examination (MMSE) at least twice during follow-up and had BPH, some of whom were taking alpha-blockers, including tamsulosin, at Chuncheon Sacred Heart Hospital from January 2009 to June 2019. This study was approved by the Clinical Research Ethics Committee of Chuncheon Sacred Heart Hospital, Hallym University.

Dementia was defined based on the presence of ICD (International Statistical Classification of Diseases and Related Health Problems) -10 diagnostic codes for AD and 1 prescription filled for dementia medications (ie, donepezil, rivastigmine, galantamine, or memantine). The study enrolled subjects with dementia defined as having mild to moderate AD (MMSE 10–26, Clinical Dementia Rating 1–2). Of these, the tamsulosin group included males with BPH who had filled prescriptions for tamsulosin. Only patients who had taken tamsulosin for >1000 days and who had undergone MMSE testing >1000 days apart were included in the tamsulosin group. Only males with mild or moderate AD who had undergone MMSE testing >1000 days apart and those who did not take any alpha-blocker, including tamsulosin were included in the no-medication group. We tested the effect of tamsulosin on cognition in mild to moderate AD using propensity score-matched logistic regression analysis. To evaluate the degree of cognitive decline, we retrospectively examined the total MMSE scores at initial and final follow-up. We compared the differences in MMSE scores between patients who took tamsulosin for >1000 days and those who did not take any alpha-blocker, including tamsulosin.

Clinical data and medical records were analyzed, and patients were excluded if they had a past or present central nervous system disease, hearing loss, or depression based on a diagnosis and subsequent treatment in the appropriate department. We collected clinical information on the patients’ maximum duration of formal education, age, body mass index (BMI), and history of smoking. Information on vascular risk factors such as hypertension, type 2 diabetes mellitus (DM), hypercholesterolemia, and cardiovascular disease, defined as a diagnosis and subsequent treatment by a physician for the respective condition, was included.

2.2 Propensity score matching and statistical analysis

After confirming normality, χ2 and Student t tests were used to compare nominal and continuous variables, respectively. Since the use of tamsulosin was not randomized in the patient group, potential confounding and selection biases were accounted for using the propensity score. A propensity score for tamsulosin use was calculated from a logistic equation for each patient. The variables listed in Table 1 were included as covariates. The propensity score for tamsulosin use ranged from 0.05 to 0.83, and, in effect, represented the probability that a patient would use tamsulosin. We sought to match each tamsulosin user to a non–tamsulosin-using patient who had a similar propensity score, in a 1:1 ratio. Propensity score matching used the macro function of SPSS (SPSS Inc, Chicago, IL). The standardized difference was measured using the Practical Meta-Analysis Effect Size Calculator. All analyses were performed using Statistical Packages for the Social Sciences for Windows ver. 22.0 (IBM Corp, Armonk, NY); P values < .05 were considered statistically significant.

Table 1:
Subject characteristics in the 2 diagnostic groups before and after matching.

3 Results

3.1 Subject characteristics

All inclusion and exclusion criteria were met by 492 men with AD and BPH. The final subjects were placed in tamsulosin (n = 68) and no-medication (n = 153) groups. There were differences in age, BMI, and presence of hypertension and cardiovascular disease between the 2 groups. After propensity score matching, each group had 68 subjects. After matching, there were no significant differences in the measured clinical characteristics, and the standardized differences of all covariates, excluding hyperlipidemia, decreased. Thus, there were no significant differences in educational attainment, BMI, smoking, and vascular risk factors such as the proportions with hypertension, DM, hyperlipidemia, or cardiovascular disease across the study groups. The mean daily doses of acetylcholine-esterase inhibitors (AChEI) and memantine during the entire follow-up period were not significantly different (Table 1).

3.2 Differences in cognitive decline between the tamsulosin and no-medication groups in patients with AD

The initial and final MMSE scores in the tamsulosin group were 19.6 ± 5.9 and 16.9 ± 7.3, respectively; those for the no-medication group were 19.0 ± 5.8 and 15.4 ± 7.1. The differences in MMSE scores did not differ significantly (P = .470) between the tamsulosin and no-medication groups (Fig. 1). The mean interval for MMSE testing between the tamsulosin and no-medication groups was not significantly different (1341.2 ± 165.4 vs 1362.0 ± 231.9 days) (Table 2).

Figure 1:
Difference in MMSE scores between the tamsulosin and no-medication groups. No med = no-medication.
Table 2:
Difference in MMSE scores between the tamsulosin and no-medication groups.

4 Discussion

This study examined possible associations between the use of tamsulosin, as treatment for BPH, and cognitive decline in males with mild to moderate AD. After propensity score matching, the clinical characteristics, including demographics and vascular risk factors, were very similar between the tamsulosin and no-medication groups. The baseline and follow-up MMSE scores after >1000 days did not differ significantly between the 2 groups. Thus, there was no significant difference in cognitive decline between the tamsulosin and no-medication groups in mild to moderate AD in this study.

A more selective α1-adrenergic antagonist is the primary therapy for patients with BPH presenting with lower urinary tract symptoms, particularly in the elderly,[18] and they are used by 80% of physicians as the first-line agent to treat this common condition in aging males.[19] Four common α1-adrenergic antagonists are recommend by the American Urological Association for the management of lower urinary tract symptoms: tamsulosin, terazosin, doxazosin, and alfuzosin.[20] Of these drugs, tamsulosin has been reported to have adverse effects on cognitive function through its selectivity for α1A subtype α1-adrenoreceptors in the brain.[9,21–24] In experimental studies using mice, suppressed expression of the α1A-adrenoreceptors was associated with poor cognitive performance,[22] whereas long-term stimulation of the α1A-adrenoreceptors in mice improved synaptic plasticity, enhanced learning and memory, and induced anti-depressant-like behavior that was reversed by the administration of an α1A-adrenoreceptor blocker.[22,23] Clinical studies have also reported conflicting findings regarding the association between the use of tamsulosin and clinical onset of AD dementia.[13,14] In addition, several studies have shown that tamsulosin crosses the blood-brain barrier (BBB) and at least 1 human study has reported decreased expression of α1A-adrenoreceptors in the prefrontal cortex of dementia patients.[21,24,25] Conversely, several studies have demonstrated that tamsulosin does not cross the BBB.[26] Therefore, to resolve this conflict, experimental studies should explore the pathophysiological mechanisms and impacts of tamsulosin in the brain on cognition.

Typical late-onset AD is likely to be driven by a complex interplay between genetic and environmental factors that develop over decades. It is now thought that ∼70% of AD risk is attributable to genetic factors.[27] The pathophysiological process of AD is thought to begin many years before the diagnosis of AD dementia. Emerging evidence from both genetic at-risk and aging cohorts suggests that there is a time lag of a decade or more between the beginning of the pathological cascade of AD and the onset of clinically evident impairment.[17] The associations observed in previous studies[13,14] were over relatively short median times, which were probably too short to cause dementia. It is possible that tamsulosin just unmasks symptoms in patients who already have preclinical or early AD, rather than actually causing it. Thus, we investigated the effect of tamsulosin on worsening of cognition in patients with mild or moderate AD, unlike the previous study.

We used the MMSE as a cognitive assessment. Using the MMSE, the cognitive decline in AD patients was found to range from a loss of 2.7 to 4.5 points annually.[28] Receiving drug therapy for AD, such as an AChEI or memantine, can reduce the rate of cognitive decline.[29,30] In a retrospective study with 92% to 95% of the patients receiving drug treatment, the overall MMSE decreased annually by 0.83 ± 2.13 points during a 2.4 ± 1.3-year follow-up period.[31] Another study showed that the mean difference in the MMSE score from baseline was –0.6 (–0.3 to –0.8) after 1 year of AChEI treatment, –2.3 (–1.9 to –2.7) after 2 years, and –3.2 (–2.7 to –3.7) after 3 years.[30] Similar to previous findings, in our study with all patients receiving medication for dementia, such as AChEI or memantine, the annual decline in MMSE score was 0.98 and 0.75 in the tamsulosin and no-medication groups, respectively.

The rate of cognitive deterioration during the course of AD varies markedly across individuals,[32,33] and is driven by various clinical factors. Although some studies suggest that sociodemographic and clinical factors, such as younger age, higher education, undernutrition, and vascular risk factors, such as hypertension, diabetes, hypercholesterolemia, aggravate the cognitive decline in AD,[34–38] other reports do not support these findings.[37,39] Cognitive test results at baseline and an MMSE score <20 at treatment onset were also associated with rapid cognitive decline in AD.[38,40] Thus, we analyzed the clinical factors that may influence cognitive decline during the course of AD. There were no significant differences in age, educational attainment, BMI, or vascular risk factors, such as the proportions with hypertension, diabetes, and hypercholesterolemia, across the groups in our study. The baseline MMSE scores did not differ significantly between the tamsulosin and no-medication groups. However, cognitive decline during the course of AD is also likely to be driven by genetic factors. One study reported that carriers of the apolipoprotein E (APOE) ε4 allele undergo accelerated cognitive decline[41] due to the allele's cumulative impact on the beta amyloid and neurofibrillary tangle biochemical pathways.[42–44] We lacked genotype information for the patients with AD. However, this hypothesis has been explored for >10 years with no resolution and the studies directly examining decline as a function of APOE genotype have produced inconsistent findings.[41,45–49]

This study has several limitations. First, it used data collected from individuals who visited a single university hospital in a regional community and is also limited by the small number of subjects. Therefore, it is difficult to generalize the results to the general population, and the possibility of selection bias must be considered. Next, our study was retrospective and we did not have detailed clinical data including genetic information, such as the APOE genotype. Future studies should examine the association between the use of alpha-blockers as a treatment for BPH and aggravation of dementia in broader patient populations with long-term follow-up.

5 Conclusion

In conclusion, this study examined possible associations between the use of tamsulosin and cognitive decline in males with mild to moderate AD. After propensity score matching for clinical factors influencing cognition, the MMSE scores obtained >1000 days apart did not differ significantly between the tamsulosin and no-medication groups. These findings suggest that tamsulosin is not associated with cognitive decline in patients with AD. Future prospective, population-based studies are needed to investigate the association between the use of tamsulosin and its impact on cognition or dementia risk.

Author contributions

Jong-Hee Sohn contributed to this work as first authors.

Jae Jun Lee and Youngmi Kim equally contributed as the corresponding author.

Sang-Hwa Lee helped acquisition and interpretation of data.

Young-Suk Kwon helped acquisition and analysis of data.

Jong-Ho Kim helped acquisition and analysis of data.

Jae Jun Lee and Youngmi Kim helped study supervision and revising paper.


[1]. Yeo JK, Choi H, Bae JH, et al. Korean clinical practice guideline for benign prostatic hyperplasia. Investig Clin Urol 2016;57:30–44.
[2]. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40.
[3]. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997;30:202–15.
[4]. Lepor H, Tang R, Meretyk S, et al. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol 1993;149:640–2.
[5]. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546–51.
[6]. Cavalli A, Lattion AL, Hummler E, et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA 1997;94:11589–94.
[7]. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 2002;99:9474–9.
[8]. Tanoue A, Nasa Y, Koshimizu T, et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest 2002;109:765–75.
[9]. Perez DM, Doze VA. Cardiac and neuroprotection regulated by alpha(1)-adrenergic receptor subtypes. J Recept Signal Transduct Res 2011;31:98–110.
[10]. Martin DJ, Lluel P, Guillot E, et al. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997;282:228–35.
[11]. Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int 2003;92:876–7.
[12]. Frankel JK, Duan Y, Albertsen PC. Is Tamsulosin linked to dementia in the elderly? Curr Urol Rep 2018;19:69.
[13]. Duan Y, Grady JJ, Albertsen PC, et al. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018;27:340–8.
[14]. 2019;Tae BS, Jeon BJ, Choi H, et al. alpha-Blocker and risk of dementia in patients with benign prostate hyperplasia: A nationwide population based study using the National Health Insurance Service database. 202:362–8.
[15]. Kaplan SA. Re: Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. J Urol 2019;201:4.
[16]. Madersbacher S, Michel MC. Re: Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Eur Urol 2018;74:522–3.
[17]. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–92.
[18]. Mancini V, Balzarro M, Illiano E, et al. Lower urinary tract symptoms in elderly men: a simple yet comprehensive approach. J Gerontol Geriatr 2018;66:245–52.
[19]. Narayan P, Tunuguntla HS. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol 2005;7: (suppl 4): S42–8.
[20]. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793–803.
[21]. Nikolic K, Filipic S, Smolinski A, et al. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of alpha-adrenergic and imidazoline receptor ligands. J Pharm Pharm Sci 2013;16:622–47.
[22]. Doze VA, Papay RS, Goldenstein BL, et al. Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol 2011;80:747–58.
[23]. Doze VA, Handel EM, Jensen KA, et al. Alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res 2009;1285:148–57.
[24]. Szot P, White SS, Greenup JL, et al. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 2007;146:471–80.
[25]. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97: (suppl 2): 34–8. discussion 44-5.
[26]. Franco-Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 2010;49:177–88.
[27]. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol 2018;25:59–70.
[28]. Aguero-Torres H, Fratiglioni L, Winblad B. Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 1998;13:755–66.
[29]. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417–22.
[30]. Wattmo C, Wallin AK, Londos E, et al. Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther 2011;3:23.
[31]. Hishikawa N, Fukui Y, Takemoto M, et al. Clinical predictors of Alzheimer's disease progression. Geriatr Gerontol Int 2018;18:929–36.
[32]. Storandt M, Grant EA, Miller JP, et al. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 2002;59:1034–41.
[33]. Hui JS, Wilson RS, Bennett DA, et al. Rate of cognitive decline and mortality in Alzheimer's disease. Neurology 2003;61:1356–61.
[34]. Stern Y, Alexander GE, Prohovnik I, et al. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol 1992;32:371–5.
[35]. Jacobs D, Sano M, Marder K, et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215–20.
[36]. Ousset PJ, Nourhashemi F, Reynish E, et al. Nutritional status is associated with disease progression in very mild Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:66–71.
[37]. Musicco M, Palmer K, Salamone G, et al. Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors. J Neurol 2009;256:1288–95.
[38]. Tchalla AE, Clement JP, Saulnier I, et al. Predictors of rapid cognitive decline in patients with mild-to-moderate Alzheimer disease: A prospective cohort study with 12-month follow-up performed in memory clinics. Dement Geriatr Cogn Disord 2018;45:56–65.
[39]. Galasko DR, Gould RL, Abramson IS, et al. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med 2000;19:1421–32.
[40]. Eldholm RS, Barca ML, Persson K, et al. Progression of Alzheimer's disease: a longitudinal study in Norwegian memory clinics. J Alzheimers Dis 2018;61:1221–32.
[41]. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467–72.
[42]. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977–81.
[43]. Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995;66:583–7.
[44]. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62–70.
[45]. Martins CA, Oulhaj A, de Jager CA, et al. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005;65:1888–93.
[46]. Kleiman T, Zdanys K, Black B, et al. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 2006;22:73–82.
[47]. Jonker C, Schmand B, Lindeboom J, et al. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998;55:1065–9.
[48]. Hoyt BD, Massman PJ, Schatschneider C, et al. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 2005;62:454–9.
[49]. Hirono N, Hashimoto M, Yasuda M, et al. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci 2003;15:354–8.

Alzheimer disease; benign prostate hyperplasia; cognition; dementia; tamsulosin

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.